<- Go Home

Journey Medical Corporation

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Market Cap

$177.0M

Volume

196.4K

Cash and Equivalents

$25.6M

EBITDA

$1.4M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$44.6M

Profit Margin

65.45%

52 Week High

$9.55

52 Week Low

$4.31

Dividend

N/A

Price / Book Value

N/A

Price / Earnings

-28.15

Price / Tangible Book Value

N/A

Enterprise Value

$176.9M

Enterprise Value / EBITDA

119.72

Operating Income

-$3.0M

Return on Equity

23.77%

Return on Assets

-2.09

Cash and Short Term Investments

$25.6M

Debt

$25.5M

Equity

$32.1M

Revenue

$68.2M

Unlevered FCF

N/A

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches